Hypoxia-Inducible Factor Linked to Differential Kidney Cancer Risk Seen with Type 2A and Type 2B VHL Mutations

ABSTRACT Clear cell carcinoma of the kidney is a major cause of mortality in patients with von Hippel-Lindau (VHL) disease, which is caused by germ line mutations that inactivate the VHL tumor suppressor gene. Biallelic VHL inactivation, due to mutations or hypermethylation, is also common in sporadic clear cell renal carcinomas. The VHL gene product, pVHL, is part of a ubiquitin ligase complex that targets the alpha subunits of the heterodimeric transcription factor hypoxia-inducible factor (HIF) for destruction under well-oxygenated conditions. All VHL mutations linked to classical VHL disease compromise this pVHL function although some missense mutations result in a low risk of kidney cancer (type 2A VHL disease) while others result in a high risk (type 2B VHL disease). We found that type 2A mutants were less defective than type 2B mutants when reintroduced into VHL−/− renal carcinoma cells with respect to HIF regulation. A stabilized version of HIF2α promoted tumor growth by VHL−/− cells engineered to produce type 2A mutants, while knock-down of HIF2α in cells producing type 2B mutants had the opposite effect. Therefore, quantitative differences with respect to HIF deregulation are sufficient to account for the differential risks of kidney cancer linked to VHL mutations.

[1]  W. Kaelin,et al.  Inhibition of HIF2α Is Sufficient to Suppress pVHL-Defective Tumor Growth , 2003, PLoS biology.

[2]  E. Rankin,et al.  Inactivation of the Arylhydrocarbon Receptor Nuclear Translocator (Arnt) Suppresses von Hippel-Lindau Disease-Associated Vascular Tumors in Mice , 2005, Molecular and Cellular Biology.

[3]  R. Klausner,et al.  Role of transforming growth factor-alpha in von Hippel--Lindau (VHL)(-/-) clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[4]  A. Harris,et al.  Differential Function of the Prolyl Hydroxylases PHD1, PHD2, and PHD3 in the Regulation of Hypoxia-inducible Factor* , 2004, Journal of Biological Chemistry.

[5]  W. Kaelin,et al.  Molecular basis of the VHL hereditary cancer syndrome , 2002, Nature Reviews Cancer.

[6]  W. Kaelin,et al.  von Hippel-Lindau gene-mediated growth suppression and induction of differentiation in renal cell carcinoma cells grown as multicellular tumor spheroids. , 1998, Cancer research.

[7]  Mirna Lechpammer,et al.  Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. , 2002, Cancer cell.

[8]  A. Vortmeyer,et al.  Hepatic vascular tumors, angiectasis in multiple organs, and impaired spermatogenesis in mice with conditional inactivation of the VHL gene. , 2003, Cancer research.

[9]  Yudong D. He,et al.  Expression profiling using microarrays fabricated by an ink-jet oligonucleotide synthesizer , 2001, Nature Biotechnology.

[10]  S. Elledge,et al.  Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. , 1999, Science.

[11]  P. O’Farrell.  Faculty Opinions recommendation of Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. , 2001 .

[12]  E. Keshet,et al.  Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[13]  O. Iliopoulos,et al.  Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors. , 2004, Molecular cancer research : MCR.

[14]  D. Duan,et al.  Inhibition of transcription elongation by the VHL tumor suppressor protein , 1995, Science.

[15]  R. Klausner,et al.  Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[16]  R. Burk,et al.  Elongin BC complex prevents degradation of von Hippel-Lindau tumor suppressor gene products. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Christopher J. Schofield,et al.  Oxygen sensing by HIF hydroxylases , 2004, Nature Reviews Molecular Cell Biology.

[18]  A. Kibel,et al.  Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C , 1995, Science.

[19]  Mircea Ivan,et al.  Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[20]  W. Krek,et al.  Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL , 2003, Nature Cell Biology.

[21]  B. Zbar,et al.  Synthetic peptides define critical contacts between elongin C, elongin B, and the von Hippel-Lindau protein. , 1999, The Journal of clinical investigation.

[22]  W. Kaelin,et al.  Clusterin is a secreted marker for a hypoxia-inducible factor-independent function of the von Hippel-Lindau tumor suppressor protein. , 2006, The American journal of pathology.

[23]  R. Raval,et al.  Regulation of E-cadherin expression by VHL and hypoxia-inducible factor. , 2006, Cancer research.

[24]  W. Kaelin,et al.  The von Hippel-Lindau protein, HIF hydroxylation, and oxygen sensing. , 2005, Biochemical and biophysical research communications.

[25]  G. Berx,et al.  VHL Promotes E2 Box-Dependent E-Cadherin Transcription by HIF-Mediated Regulation of SIP1 and Snail , 2006, Molecular and Cellular Biology.

[26]  J R Griffiths,et al.  Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. , 2005, Human molecular genetics.

[27]  P. Ratcliffe,et al.  Independent function of two destruction domains in hypoxia‐inducible factor‐α chains activated by prolyl hydroxylation , 2001, The EMBO journal.

[28]  W. Linehan,et al.  Germline mutations in the von Hippel–Lindau disease tumor suppressor gene: Correlations with phenotype , 1995, Human mutation.

[29]  H. Moch,et al.  Chemokine receptor CXCR4 downregulated by von Hippel–Lindau tumour suppressor pVHL , 2003, Nature.

[30]  L. del Peso,et al.  Identification of a functional hypoxia-responsive element that regulates the expression of the egl nine homologue 3 (egln3/phd3) gene. , 2005, The Biochemical journal.

[31]  Michael I. Wilson,et al.  C. elegans EGL-9 and Mammalian Homologs Define a Family of Dioxygenases that Regulate HIF by Prolyl Hydroxylation , 2001, Cell.

[32]  Richard D Klausner,et al.  The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. , 2002, Cancer cell.

[33]  M. Ivan,et al.  Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel–Lindau protein , 2000, Nature Cell Biology.

[34]  L. Gunaratnam,et al.  Hypoxia Inducible Factor Activates the Transforming Growth Factor-α/Epidermal Growth Factor Receptor Growth Stimulatory Pathway in VHL-/- Renal Cell Carcinoma Cells* , 2003, Journal of Biological Chemistry.

[35]  J. Meller,et al.  von Hippel-Lindau tumor suppressor: not only HIF's executioner. , 2004, Trends in molecular medicine.

[36]  B. Ebert,et al.  Failure to prolyl hydroxylate hypoxia‐inducible factor α phenocopies VHL inactivation in vivo , 2006 .

[37]  G. Semenza,et al.  Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B. , 2006, Cancer research.

[38]  R. Figlin,et al.  A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  I. Fidler,et al.  Orthotopic implantation is essential for the selection, growth and metastasis of human real cell cancer in nude mice , 1990, Cancer and Metastasis Reviews.

[40]  Charles C Wykoff,et al.  HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. , 2002, Cancer cell.

[41]  M. Lerman,et al.  Identification of intragenic mutations in the von Hippel-Lindau disease tumour suppressor gene and correlation with disease phenotype. , 1994, Human molecular genetics.

[42]  W. Rathmell,et al.  In vitro and In vivo Models Analyzing von Hippel-Lindau Disease-Specific Mutations , 2004, Cancer Research.

[43]  M. Ivan,et al.  HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O2 Sensing , 2001, Science.

[44]  S. Richard,et al.  The growing family of hereditary renal cell carcinoma. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[45]  M. Wood,et al.  Regulation of HIF prolyl hydroxylases by hypoxia‐inducible factors , 2004, Journal of cellular biochemistry.

[46]  W. Kaelin,et al.  Regulation of Hypoxia-Inducible mRNAs by the von Hippel-Lindau Tumor Suppressor Protein Requires Binding to Complexes Containing Elongins B/C and Cul2 , 1998, Molecular and Cellular Biology.

[47]  Fan,et al.  Cellular proteins that bind the von Hippel-Lindau disease gene product: mapping of binding domains and the effect of missense mutations. , 1995, Cancer research.

[48]  Xiaoen Wang,et al.  Development of a high metastatic orthotopic model of human renal cell carcinoma in nude mice: benefits of fragment implantation compared to cell-suspension injection , 1999, Clinical & Experimental Metastasis.

[49]  R. Klausner,et al.  Identification of the von Hippel-lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[50]  Keiichi I Nakayama,et al.  VHL-box and SOCS-box domains determine binding specificity for Cul2-Rbx1 and Cul5-Rbx2 modules of ubiquitin ligases. , 2004, Genes & development.

[51]  R. Conaway,et al.  The Rbx1 subunit of SCF and VHL E3 ubiquitin ligase activates Rub1 modification of cullins Cdc53 and Cul2. , 1999, Genes & development.

[52]  Adrian L. Harris,et al.  Hypoxia — a key regulatory factor in tumour growth , 2002, Nature Reviews Cancer.

[53]  L. del Peso,et al.  The von Hippel Lindau/Hypoxia-inducible Factor (HIF) Pathway Regulates the Transcription of the HIF-Proline Hydroxylase Genes in Response to Low Oxygen* , 2003, Journal of Biological Chemistry.

[54]  S. McKnight,et al.  A Conserved Family of Prolyl-4-Hydroxylases That Modify HIF , 2001, Science.

[55]  W. Kaelin,et al.  Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. , 2005, Cancer cell.

[56]  David I Stuart,et al.  Structural basis for the recognition of hydroxyproline in HIF-1 alpha by pVHL. , 2002, Nature.

[57]  M. Karno,et al.  Renal cell carcinoma. , 1956, Bulletin. Tufts-New England Medical Center.

[58]  P. Jemth,et al.  Renal cell carcinoma risk in type 2 von Hippel–Lindau disease correlates with defects in pVHL stability and HIF-1α interactions , 2006, Oncogene.

[59]  W. Kaelin,et al.  Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. , 1999, Science.

[60]  M. Ivan,et al.  Structure of an HIF-1α-pVHL Complex: Hydroxyproline Recognition in Signaling , 2002, Science.

[61]  R. Burk,et al.  VHL Induces Renal Cell Differentiation and Growth Arrest through Integration of Cell-Cell and Cell-Extracellular Matrix Signaling , 2001, Molecular and Cellular Biology.

[62]  B. Ebert,et al.  Failure to prolyl hydroxylate hypoxia-inducible factor alpha phenocopies VHL inactivation in vivo. , 2006, The EMBO journal.

[63]  G. Semenza,et al.  Stromal Cell–Derived Factor-1α and CXCR4 Expression in Hemangioblastoma and Clear Cell-Renal Cell Carcinoma: von Hippel-Lindau Loss-of-Function Induces Expression of a Ligand and Its Receptor , 2005 .

[64]  W. Kaelin,et al.  Proline hydroxylation and gene expression. , 2005, Annual review of biochemistry.

[65]  Sandro Santagata,et al.  A HIF1α Regulatory Loop Links Hypoxia and Mitochondrial Signals in Pheochromocytomas , 2005, PLoS genetics.

[66]  S. White,et al.  HIF-1α binding to VHL is regulated by stimulus-sensitive proline hydroxylation , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[67]  Michael I. Wilson,et al.  Targeting of HIF-α to the von Hippel-Lindau Ubiquitylation Complex by O2-Regulated Prolyl Hydroxylation , 2001, Science.

[68]  Patrick H. Maxwell,et al.  Contrasting Properties of Hypoxia-Inducible Factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-Associated Renal Cell Carcinoma , 2005, Molecular and Cellular Biology.

[69]  C. Wykoff,et al.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis , 1999, Nature.

[70]  A. Kibel,et al.  Tumour suppression by the human von Hippel-Lindau gene product , 1995, Nature Medicine.

[71]  M. Ivan,et al.  von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. , 2001, Human molecular genetics.

[72]  P. Ratcliffe,et al.  Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. , 2001, Human molecular genetics.

[73]  R. Klausner,et al.  Characterization of the VHL tumor suppressor gene product: localization, complex formation, and the effect of natural inactivating mutations. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[74]  R. Klausner,et al.  The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[75]  W. Kaelin,et al.  Role of VHL gene mutation in human cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[76]  L. Gunaratnam,et al.  Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL-/- renal cancer. , 2005, Cancer research.

[77]  R. Jaenisch,et al.  Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[78]  David G. Watson,et al.  Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. , 2005, Cancer cell.

[79]  W. Kaelin.  The Von Hippel-Lindau Tumor Suppressor Gene and Kidney Cancer , 2004, Clinical Cancer Research.

[80]  I. Fidler,et al.  In vivo selection of human renal cell carcinoma cells with high metastatic potential in nude mice , 1989, Clinical & Experimental Metastasis.

[81]  L. Gunaratnam,et al.  Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cells. , 2003, The Journal of biological chemistry.

[82]  R. Klausner,et al.  The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. , 1997, Proceedings of the National Academy of Sciences of the United States of America.